Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.

Alessia Alunno Aurélie NajmXavier MarietteGabriele De MarcoJenny EmmelLaura MasonDennis G McGonaglePedro M Machado

Published in: Annals of the rheumatic diseases (2021)

Although there is emerging evidence about immunomodulatory therapies for the management of COVID-19, conclusive data are scarce with some conflicting data. Since glucocorticoids seem to improve survival in some subsets of patients, RCTs comparing glucocorticoids alone versus glucocorticoids plus anticytokine/immunomodulatory treatment are warranted. This systematic literature review informed the initiative to formulate EULAR 'points to consider' on COVID-19 pathophysiology and immunomodulatory treatment from the rheumatology perspective.

Keyphrases

coronavirus disease
end stage renal disease
electronic health record
newly diagnosed
ejection fraction
prognostic factors
machine learning
replacement therapy
systemic lupus erythematosus
peripheral blood
free survival